| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/16/2005 | CN1189482C Novel angiogenesis inhibitor |
| 02/16/2005 | CN1189479C Use of leptin in inhibition of endothelial cell proliferation |
| 02/16/2005 | CN1189467C Pharmaceutically active sulfonamide derivatives |
| 02/16/2005 | CN1189168C Use of (-)-(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2-diabetes, hyperlipidemia and hyperuricemia |
| 02/15/2005 | US6855830 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 02/15/2005 | US6855823 Selective iGluR5 receptor antagonists |
| 02/15/2005 | US6855722 Substituted indoles and their use as integrin antagonists |
| 02/15/2005 | US6855719 Nitrogen compounds such as 2-(3-Chloroanilino)-4-(2-methyl-imidazo(1,2a)pyrid-3-yl)pyrimidine, used as cyclin dependent kinase inhibitors or as anticarcinogenic agents |
| 02/15/2005 | US6855693 Peptide for use in the treatment of cell damage caused by ischemia |
| 02/15/2005 | US6855512 Phenylacetic or heteroarylacetic acid derivatives; retinoid like activity |
| 02/14/2005 | CA2477359A1 Pyruvate enriched onion extract |
| 02/10/2005 | WO2005012268A1 Sulfonamide derivative having isoxazole ring |
| 02/10/2005 | WO2005011813A2 Treatment of ocular disease |
| 02/10/2005 | WO2005011725A2 Anti-angiogenetic agent and its use, in particular in cancer treatment |
| 02/10/2005 | WO2005011704A1 Product containing prostaglandin |
| 02/10/2005 | WO2004112748A3 Rate controlled release of a pharmaceutical agent in a biodegradable device |
| 02/10/2005 | WO2004080933A3 Isolation of lutein from alfalfa |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050032914 Lutein/zeaxanthin for glare protection |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032865 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 02/10/2005 | US20050032862 Preparing a novel crystal form by sonication and temperature oscillation of a suspension; filtered and dried faster; treating cardiovascular disorders |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032820 Novel spiro compounds |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032768 pentsaaacycle manganese complexes used as mimetics for oxidoreductase enzymes, for the treatment of age-related macular degeneration, diabetic retinopathy and edema; vision defects |
| 02/10/2005 | US20050032752 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032691 Methods for treating glaucoma |
| 02/10/2005 | US20050032214 Cell-specific expression/replication vector |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050031669 a biodegradable polymer (glycolic acid-lactic acid copolymer) with a hydrophobic or hydrophobically enhanced drug; sustained release ocular implants; vision defects |
| 02/10/2005 | US20050031646 Immunogens; polysaccharide conjugate antigens derived from pathogenic bacterium conjugated to protein D from Haemophilus influenzae |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031540 Visco dye |
| 02/10/2005 | CA2534214A1 Treatment of ocular disease |
| 02/09/2005 | EP1505068A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1504760A1 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 02/09/2005 | EP1504007A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 02/09/2005 | EP1503984A1 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503777A1 7-hydroxy chromones as potent antioxidants |
| 02/09/2005 | EP1503757A2 Tyrosine kinase inhibitors |
| 02/09/2005 | EP1503752A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503746A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 02/09/2005 | EP1503730A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1280525B1 Methods and compositions for modulating alpha adrenergic receptor activity |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578772A Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 02/09/2005 | CN1578768A Anthranilic acid amides and pharmaceutical use thereof |
| 02/09/2005 | CN1578670A Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1575814A Medicinal composition for eyes, it's preparing process and use thereof |
| 02/09/2005 | CN1575813A Preparation for eyes and preparing method thereof |
| 02/09/2005 | CN1188416C Oxathiepino [6,5-b]dihydropyridines,and related compositions and preparation methods |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188412C Process for preparing crystalline form 1 of cabergoline |
| 02/09/2005 | CN1188410C Nonsteroid IL-5 inhibitor, its preparation method and medical composition containing the same inhibitor |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188399C New pyrazolone compound and eye plastic lens made therefrom |
| 02/09/2005 | CN1188113C Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 02/08/2005 | US6852751 Difluorobutyric acid metalloprotease inhibitors |
| 02/08/2005 | US6852750 Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852736 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 02/08/2005 | US6852726 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852718 Selective 5-HT2A antagonists useful in treatment or prevention of CNS conditions |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | US6852311 Ophthalmic ointments for treating infective eye disease |
| 02/03/2005 | WO2005009992A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | WO2005009954A2 Method for modulating calcium ion-release-activated calcium ion channels |
| 02/03/2005 | WO2005009940A1 Novel aminobenzophenone compounds |
| 02/03/2005 | WO2005009539A2 Compounds for inflammation and immune-related uses |
| 02/03/2005 | WO2005009460A2 Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| 02/03/2005 | WO2005009459A1 Ophthalmic compositions comprising trefoil factor family peptides |
| 02/03/2005 | WO2005009436A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | WO2005009427A1 Curative medicine for allergosis |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027125 Intensifiers of adenosine receptors for cardiac arrhythmia |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026980 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026901 Antihistaminic spiro compounds |
| 02/03/2005 | US20050026892 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026824 Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same |